The next frontier in precision medicine and health innovation for preventing and treating inflammation and metabolic disease.

New insights on how ABA might improve diabetes bring it one step closer to clinical testing in pre-diabetic patients

BLACKSBURG, VA—July 1, 2020—Researchers at the NIMML Institute and Biotherapeutics have characterized how abscisic acid (ABA)-enriched fig extract promotes glucose tolerance and insulin...

News / July 01 2020

BioTherapeutics, Inc. Announces Publication of Results from Phase 1 Human Clinical Trial of Abscisic Acid in Healthy Volunteers

BLACKSBURG, VA—August 1, 2019—BioTherapeutics, Inc., (BTI) a clinical-stage biotech company that synergistically combines the power of advanced...

News / August 01 2019

Accelerating the Path to Cures: New Insights on the Application of Advanced Computational Approaches in Drug Development

BLACKSBURG, VA—April 26, 2018—Developing a new drug in the U.S. costs approximately $2.6 billion over the course of 10-15 years. The chances of success are slim: one in 10,000. How...

News / April 26 2018

Our Purpose

Biotherapeutics Inc. (BTI) is a science-based biotechnology company that integrates Nutritionals, Therapeutics and IT to advance interventions for preventing and treating autoimmune and metabolic diseases.

See more about us

BioTherapeutics Partners with Euromed to Launch an Abscisic Acid Nutritional Ingredient to Market

BLACKSBURG, VA- September 25, 2017 — BioTherapeutics (BTI) is partnering with Euromed, a leading manufacturer of botanical extracts to develop an abscisic acid (ABA) nutritional...

News / September 25 2017

BioTherapeutics is Developing Abscisic Acid as a Nutraceutical for Glycemic Control

BLACKSBURG, VA —June 15, 2017— BioTherapeutics, Inc. (BTI) reported the beneficial effects of abscisic acid (ABA) on glycemic control and inflammation in a seminal article published...

News / June 15 2017

Artificial Intelligence Systems for Modeling the Gut

BLACKSBURG, VA —May 21, 2017—The BioTherapeutics Inc. team has developed a revolutionary computational pipeline to test and predict the efficacy of existing and novel treatments...

News / May 21 2017

BioTherapeutics CEO Named 2017 Innovator of the Year by Roanoke-Blacksburg Technology Council

BLACKSBURG, VA — April 24, 2017—The Roanoke-Blacksburg Technology Council (RBTC) recognized a talented group of companies and individuals at its annual TechNite awards banquet, which...

News / April 24 2017

BioTherapeutics Recruits Director of Translational Informatics and Scientific Director

BLACKSBURG, VA — April 1, 2017 — BioTherapeutics, Inc. (BTI) announced today that Drs. Pinyi Lu and Andrew Leber have joined the company to lead efforts aimed at broadening...

News / April 06 2017

Now Hiring

Interested in becoming a part of the BTI team? Take a look at our job openings

View all positions

A Vision for Personalized Medicine and Health

BLACKSBURG, VA.—March 22, 2017 – Studying the human immune system is like trying to work a vast, multidimensional jigsaw puzzle with pieces that are constantly changing shape. Billions...

News / March 22 2017

LANCL2: A Novel Therapeutic Target for Influenza

BLACKSBURG, VA. February 28, 2017—The BioTherapeutics (BTI) team has recently explored the potential of activating lanthionine synthetase C-like 2 (LANCL2) to treat infectious diseases,...

News / February 28 2017

NLRX1: A New Therapeutic Target for Inflammatory Bowel Disease

BLACKSBURG, VA. February 27, 2017 – The BioTherapeutics team recently characterized a new mechanism of action underlying the regulation of immunity and metabolism by nucleotide...

News / February 28 2017

NIMML at BTI

NIMML uses innovation to tackle challenges in infectious, immune-mediated, and chronic inflammatory disease research. BTI was founded in 2008 by Dr. Josep Bassaganya-Riera as a result of the technology developed at VT’s Nutritional Immunology and Molecular Medicine Laboratory (NIMML).

Go to NIMML Website